Article

Express Scripts, Walgreens Group Purchasing Partnership Highlights SPT Week in Review

Author(s):

Top news of the week from Specialty Pharmacy Times.

5. Modified Antiviral Drug Could Cure HIV

Crystalized dolutegravir may be able to reach viral reservoirs and cure HIV. Read more.

4. Oncolytic Viruses Put Immune System on High Alert

Combining oncolytic viruses and immunotherapies may fight cancer more effectively. Read more.

3. Brain Stimulation May Relieve Multiple Sclerosis-Associated Fatigue

Deep transcranial stimulation could provide more relief from fatigue among multiple sclerosis patients compared with other treatments. Read more.

2. Enzalutamide Meets Phase 3 Endpoints in Prostate Cancer

Enzalutamide (Xtandi) demonstrates a significant reduction in metastasis or death from castration-resistant prostate cancer.

Read more.

1. Express Scripts, Walgreens Partner to Expand Group Purchasing of Specialty Drugs

The new purchasing efforts may help increase biosimilar uptake and lower drug costs. Read more.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards